Navigation Links
Endo Pharmaceuticals Appoints William Montague to Board of Directors
Date:2/26/2009

n where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the tender of a majority of the outstanding shares of common stock of Indevus; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditi
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 The family of a Vermont ... a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his ... LLP reports. According to the complaint, which was filed ... on July 25th, the decedent had been taking Xarelto ... brain bleed that ultimately led to his death on ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 Frozen ... Women are more likely to develop this nasty condition which ... and 60, and can last up to two and half ... known as frozen shoulder, and with good reason: it can ... your shirt — that is, if you aren't in too ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... a PET scan may interfere with the results seen, says ... emission tomography (PET) or computed tomography (CT) scan is done ... evaluate the effect of treatment on an already diagnosed malignant ... in the body that can be traced with the help ...
... have reportedly succeeded in generating sperm// and ovarian cells ... for Stem Cell Biology in Sheffield said that "the ... sperm and eggs to use in assisted conception treatments". ... with infertility. This research will allow embryonic stem cells ...
... processed meat can increase your chance of having colorectal ... the National Cancer Institute. ,Colon and rectum together ... cancer is also called colorectal cancer. Cancer of the ... malignant cells within the lining of colon or rectum. ...
... in schizophrenic patients with the help of seroquel ... is a chronic severe disabling mental illness. Some ... seen or heard, feelings of being persecuted, becoming ... symptomatically, but only one in five patients have ...
... Researchers had been able to find out why the diabetes ... University of Utah had found that the drug TZDs activates ... This is situated in the collecting duct of the kidney. ... in the body and causes edema. ,TZD drugs are ...
... inflammations of the gum may increase the risk of ... early in life. ,According to a research study ... Conference on Prevention of Dementia held in US, periodontal ... people. ,Alzheimer’s disease affects the brain cells and ...
Cached Medicine News:
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... SIPP International Industries Inc. (OTCBB: SIPN), ... hospitality and medical technology industries announced today that they ... Japanese Consulting firm based in Osaka Japan. Upon completion ... residual revenues within three months.  FVJ ...
... Jan. 17, 2012 Bayer HealthCare today announced latest ... the Phase III CORRECT ( Co lo r ectal ... ebo after failure of standard t herapy) trial. ... improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
Calcitonin RIA Kit...
... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: